Barr challenges Sanofi-Aventis patents on prostate drug

Sept 25 (Reuters) - Barr Pharmaceuticals Inc BRL.N said its Barr Laboratories Inc unit has challenged the patents listed by Sanofi-Aventis U.S. LLC (SASY.PA) on uroxatral, its treatment for enlargement of the prostate.

Barr had received U.S. regulatory nod in June for filing a generic version of the drug and the company had notified the patent holder, it said in a statement. On Sept. 21, Sanofi-Aventis filed a patent suit in a U.S. federal court to prevent Barr from proceeding with marketing of the product. (Reporting by Neetha Mahadevan in Bangalore)